First National Hand Health Month Empowers People to Live a Hands-On Life USA - English USA - English

Reddit AMA and Physician Content Creators Highlight the Observance and Dupuytren's Contracture Hand Condition

MALVERN, Pa., Sept. 2, 2025 /PRNewswire/ -- Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today the inaugural National Hand Health Month, happening this September. Endo created the observance to spotlight the vital role our hands play in connecting us to people and activities and the expertise of hand specialists in maintaining hand health. Among the highlights of National Hand Health Month will be stories of patients living with Dupuytren's contracture, including treatment with XIAFLEX^® (collagenase clostridium histolyticum), the only FDA-approved nonsurgical treatment for the condition when a "cord" can be felt.

"During Hand Health Month, we have a powerful opportunity to raise awareness, spark meaningful conversations and empower patients to take control of their hand health," said Stephanie Wenstrup, Executive Director, Orthopedics Marketing at Endo. "We're passionate about supporting those affected by Dupuytren's contracture because we believe our hands are more than functional. They are fundamental to how we connect, create, and care for the people and activities that matter most."

Reddit AMA
Dr. Damon Adamany, a leading hand specialist and orthopedic surgeon, and Steve Riden, a XIAFLEX patient, will answer questions about Dupuytren's contracture, hand health, and more during a Reddit "Ask Me Anything" (AMA) on Wednesday, September 17 at 3 p.m. ET. People can submit questions in advance or join live to take part in the discussion.

"I look forward to joining Steve to raise awareness about hand health, Dupuytren's contracture, and nonsurgical treatment options," said Dr. Adamany. "In my practice, I see many patients who have lived with the symptoms of Dupuytren's contracture and other hand conditions unnecessarily, and I hope to encourage people to take action rather than accept limits."

Steve has been sharing his Dupuytren's contracture story since 2022, when he participated in Endo's Coffee & Cords video series as an untreated Dupuytren's sufferer. Earlier this year, a branded commercial called Steve's Journey highlighted Steve's treatment and recovery.

"I believe in a hands-on life, and that's why I continue to share my Dupuytren's contracture journey, including my treatment with XIAFLEX," said Steve. "Since I first talked about my Dupuytren's contracture, people ask me about my hands, seek my advice about living with the condition, and even tell me how my story helped them get diagnosed and treated."

Digital and Social Hand Health Month Activities
Throughout September, Endo and leading physicians will share information about National Hand Health Month and Dupuytren's contracture on social and digital platforms, including XIAFLEX social media channels and Endo's corporate website.

The company partnered with two healthcare providers who will share medical information and awareness about Dupuytren's contracture with their social media audiences. Their efforts are designed to raise awareness of hand health and the symptoms of Dupuytren's contracture, as well as encourage people to find a hand specialist and ask for nonsurgical treatment options like XIAFLEX.

About National Hand Health Month
Our hands are essential to almost every aspect of daily life—from holding a loved one's hand and cooking for our families to throwing a ball with a grandchild to playing golf with a friend. National Hand Health Month highlights the importance of maintaining hand health and function and emphasizes the crucial role our hands play in our lives. Learn about an underdiagnosed hand condition and unleash the joy of a hands-on life at HandHealthTreatment.com.

About Dupuytren's Contracture
Dupuytren's contracture is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. As Dupuytren's contracture progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities. Dupuytren's contracture affects an estimated 13 million Americans.^*

WHAT IS XIAFLEX^®?
XIAFLEX is a prescription medicine used to treat adults with Dupuytren's contracture when a "cord" can be felt. It is not known if XIAFLEX is safe and effective in children under the age of 18.

IMPORTANT SAFETY INFORMATION FOR XIAFLEX
Do not receive XIAFLEX if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.

XIAFLEX can cause serious side effects, including:

• Tendon rupture or ligament damage. Receiving an injection of XIAFLEX may cause damage to a tendon or ligament in your hand and cause it to break or weaken. This could require surgery to fix the damaged tendon or ligament. Call your healthcare provider right away if you have trouble bending your injected finger (towards the wrist) after the swelling goes down or you have problems using your treated hand after your follow-up visit
• Nerve injury or other serious injury of the hand. After finger procedures, some people developed tears in the skin (lacerations), and local skin and soft-tissue necrosis (death of skin cells). Some lacerations and necrosis required skin grafting, or other surgery including amputation. Call your healthcare provider right away if you get numbness, tingling, increased pain, or tears in the skin (laceration) in your treated finger or hand after your injection or after your follow-up visit
• Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX because it contains foreign proteins. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
• hives
• swollen face
• breathing trouble
• chest pain
• low blood pressure
• dizziness or fainting
• Fainting. Fainting (passing out) or near fainting can happen in people who receive XIAFLEX, especially following finger procedures
  If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away.
• Increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.

Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, or have a bleeding problem or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines if you are unsure.

The most common side effects with XIAFLEX for the treatment of Dupuytren's contracture include:

• swelling of the injection site or the hand
• bruising or bleeding at the injection site
• pain or tenderness of the injection site or the hand
• swelling of the lymph nodes (glands) in the elbow or armpit
• itching
• breaks in the skin
• redness or warmth of the skin
• pain in the armpit

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.

Rx Only

Click for full Prescribing Information, including Medication Guide.

About Endo
Endo, a wholly owned subsidiary of Mallinckrodt plc, is a diversified therapeutics manufacturer boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This release contains forward-looking statements, including with regard to XIAFLEX the potential of this product to improve health and treatment outcomes, and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of each of Endo's and Mallinckrodt's recent emergences from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with XIAFLEX; and other risks identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Mallinckrodt's and Endo's most recent Annual Reports on Form 10-K, Mallinckrodt's Registration Statement on Form S-4, as amended, and other filings with the SEC, all of which are available on its website. The forward-looking statements made herein speak only as of the date hereof and we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law.

* Dupuytren's Contracture prevalence estimation calculation in the US: Average Dupuytren's contracture prevalence in the US (5%) multiplied by US adult population (~258 million adults per 2020 US Census data) = ~ 13 million.

SOURCE Endo USA, Inc.